摘要
目的观察奥沙利铂联合卡培他滨治疗晚期直肠癌的疗效及安全性。方法选取2005年9月至2009年12月期间收治的晚期直肠癌患者114例,所有患者均接受奥沙利铂联合卡培他滨治疗,具体方案为奥沙利铂120 mg/m2,静脉滴注2 h,第1天;卡培他滨2 500 mg/m2,口服,每日2次,第1～14天。均以21 d为1个周期,至少完成2个周期,随访2年。结果 114例患者中,部分缓解46例,疾病稳定43例,疾病进展25例,总有效率为40.35%;1年生存率为55.26%,2年生存率为21.93%。该治疗方案的主要不良反应包括神经毒性、手足综合征、消化道反应、骨髓抑制等,但均不甚严重,主要为Ⅰ度或Ⅱ度。结论奥沙利铂联合卡培他滨治疗晚期直肠癌患者疗效好,不良反应较轻。
Objective To investigate the therapeutic efficacy and safety of oxaliplatin combined with capecitabine in the treatment of pa-tients with advanced rectal cancer. Methods A hundred and fourteen patients with advanced rectal cancer admitted to the oncology de-partment of this hospital from September 2005 to December 2009 were given oxaliplatin combined with capecitabine, and the concrete regimen was oxaliplatin 120 mg/m^2 by intravenous drip for 2 h on 1 d, oral capecitabine 2 500 mg/m^2, twice daily, from 1 d to 14 d, with 21 d as a cycle of treatment. All patients received at least 2 cycles and were followed up for 2 years after treatment. Results Among 114 cases of advanced rectal cancer, 46 cases had partial remission, 43 cases had stable disease, 25 cases had disease progression, with the total effective rate of 40.35%.The one-year-survival rate was 55.26% （63/114）,and the two-year-survival rate was 21.93% （25/114）. The major adverse reactions included neurotoxicity, hand- foot syndrome, gastrointestinal adverse reaction, myelosuppression, etc. and their classification was not too serious and mainly degreeⅠ and degree Ⅱ. Conclusion Oxaliplatin combined with capecitabine has good efficacy in the treatment of advanced rectal cancer with mild adverse reactions.
出处
《中国药业》
CAS
2012年第21期58-59,共2页
China Pharmaceuticals
关键词
奥沙利铂
卡培他滨
晚期直肠癌
oxaliplatin
capecitabine
advanced rectal cancer
